Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · Chief Executive Officer | May 29, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 290,687 |
Last balance in matching sequence
After 2019-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-29 · Sale · Disposed 2,200 · Balance 294,337 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 2 · 2019-05-29 · Sale · Disposed 725 · Balance 293,612 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 3 · 2019-05-30 · Sale · Disposed 1,425 · Balance 292,187 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 4 · 2019-05-30 · Sale · Disposed 1,500 · Balance 290,687 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 332,243 |
Reported balance
Holding disclosure · report date 2019-05-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 332,243 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2018 Filed Apr 30, 2018 16:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $42.63 | $166,257.00 |
DisclosureSEC source: 0001209191-18-026838 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 189,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.25 to $43.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 16:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $42.60 | $46,860.00 |
DisclosureSEC source: 0001209191-18-026838 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 193,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.50 to $42.775. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 16:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,300 | $41.99 | $138,567.00 |
DisclosureSEC source: 0001209191-18-026838 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 194,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.35 to $42.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 12, 2018 Filed Apr 12, 2018 18:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,200 | $43.69 | $52,428.00 |
DisclosureSEC source: 0001209191-18-024774 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 197,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.35 to $44.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 12, 2018 Filed Apr 12, 2018 18:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,200 | $42.63 | $136,416.00 |
DisclosureSEC source: 0001209191-18-024774 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 198,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.10 to $43.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 18:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $41.37 | $16,548.00 |
DisclosureSEC source: 0001209191-18-024774 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 202,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.275 to $41.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 18:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,000 | $40.77 | $163,080.00 |
DisclosureSEC source: 0001209191-18-024774 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 202,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.25 to $41.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $38.40 | $7,680.00 |
DisclosureSEC source: 0001209191-18-021844 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.30 to $38.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $37.68 | $56,520.00 |
DisclosureSEC source: 0001209191-18-021844 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 206,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.15 to $38.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,700 | $36.63 | $98,901.00 |
DisclosureSEC source: 0001209191-18-021844 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 208,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 27, 2018 Filed Apr 3, 2018 18:55 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $38.40 | $7,680.00 |
DisclosureSEC source: 0001209191-18-023327 · doc4a.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 206,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.30 to $38.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 26, 2018 Filed Mar 27, 2018 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,200 | $41.12 | $49,344.00 |
DisclosureSEC source: 0001209191-18-021844 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 210,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.85 to $41.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 26, 2018 Filed Mar 27, 2018 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,200 | $39.72 | $127,104.00 |
DisclosureSEC source: 0001209191-18-021844 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 212,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.25 to $40.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 16, 2018 Filed Mar 19, 2018 16:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,300 | $42.59 | $55,367.00 |
DisclosureSEC source: 0001209191-18-020585 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 215,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.45 to $43.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 16, 2018 Filed Mar 19, 2018 16:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,100 | $41.75 | $129,425.00 |
DisclosureSEC source: 0001209191-18-020585 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 216,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.20 to $42.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 16:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,600 | $42.95 | $68,720.00 |
DisclosureSEC source: 0001209191-18-020585 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 219,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.75 to $43.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 16:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,800 | $41.87 | $117,236.00 |
DisclosureSEC source: 0001209191-18-020585 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 221,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.55 to $42.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $46.65 | $13,995.00 |
DisclosureSEC source: 0001209191-18-019643 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 224,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.575 to $46.725. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 700 | $46.17 | $32,319.00 |
DisclosureSEC source: 0001209191-18-019643 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 224,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.50 to $46.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 22, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,400 | $45.00 | $63,000.00 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 6 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 225,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F8 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.70 to $45.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 22, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,600 | $44.03 | $70,448.00 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 226,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.60 to $44.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 22, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,600 | $42.74 | $68,384.00 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 228,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.45 to $43.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,911 | $44.55 | $129,685.05 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 229,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.10 to $45.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,589 | $43.60 | $69,280.40 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 232,589 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.05 to $44.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 19:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,700 | $45.28 | $393,936.00 |
DisclosureSEC source: 0001209191-18-012730 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $48.43 | $14,529.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 8 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 242,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F8 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.30 to $48.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,100 | $47.91 | $244,341.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 7 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 243,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.25 to $48.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,600 | $46.55 | $74,480.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 6 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 248,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.15 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,000 | $45.44 | $136,320.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 249,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · derivative · entry 10 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F11 · derivative.exercise_date: Fully vested. F12 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 9 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $48.25 | $14,475.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 252,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,767 | $47.56 | $226,718.52 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 253,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.15 to $48.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,433 | $46.71 | $113,645.43 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 257,945 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.10 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $45.58 | $113,950.00 |
DisclosureSEC source: 0001209191-18-011662 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 260,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 19:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,100 | $49.25 | $152,675.00 |
DisclosureSEC source: 0001209191-18-010193 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 262,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.825 to $49.70 The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 19:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,800 | $48.42 | $280,836.00 |
DisclosureSEC source: 0001209191-18-010193 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 265,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.80 to $48.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 19:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $46.94 | $46,940.00 |
DisclosureSEC source: 0001209191-18-010193 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 271,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.65 to $47.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 19:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $45.05 | $4,505.00 |
DisclosureSEC source: 0001209191-18-010193 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 272,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 13, 2018 Filed Feb 14, 2018 19:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,000 | $45.10 | $451,000.00 |
DisclosureSEC source: 0001209191-18-010193 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 272,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $45.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $41.70 | $12,510.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 6 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 282,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $40.79 | $16,316.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 283,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.30 to $40.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $38.68 | $15,472.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 283,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.20 The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $37.43 | $41,173.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 283,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.00 to $38.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $36.59 | $80,498.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.95 to $36.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 17:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,400 | $37.15 | $163,460.00 |
DisclosureSEC source: 0001209191-18-009256 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 287,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.80 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008505 · doc4.xml · derivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2025-02-06 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:42 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008505 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,675 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,100 | $36.98 | $77,658.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 6 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.90 to 37.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,100 | $36.54 | $222,894.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 293,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.85 to $36.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.